Fast Five Quiz: Radiation Therapy for Metastatic and Advanced Prostate Cancer

Evelyn S. Marienberg, MD


November 08, 2022

According to the National Comprehensive Cancer Network (NCCN) guidelines, a patient with a life expectancy > 5 years should receive EBRT plus ADT plus abiraterone as initial treatment for locally advanced disease. EBRT alone or brachytherapy alone may be used for patients with a life expectancy of > 10 years who are classified as low risk or favorable intermediate risk, according to the NCCN guidelines. SBRT may be used with the appropriate technology, physics, and clinical expertise for limited metastatic disease to the vertebra or paravertebral region when ablation is the goal; or in patients with oligometastatic progression where progression-free survival is the goal; and in patients who have a lesion in or immediately adjacent to a previously irradiated treatment field.

Learn more about radiation treatment of metastatic and advanced prostate cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.